NCT02939118
Completed
N/A
A One-Year, Multicenter, Observational, Follow-up Safety Study in Subjects Previously Implanted With VC-01™ Combination Product
ViaCyte0 sites51 target enrollmentNovember 7, 2016
ConditionsType 1 Diabetes Mellitus
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Type 1 Diabetes Mellitus
- Sponsor
- ViaCyte
- Enrollment
- 51
- Primary Endpoint
- Incidence of adverse events reported during the study.
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose of this trial is to evaluate the long-term safety in subjects previously implanted with VC-01™ combination product.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Previous implantation of VC-01™ combination product with subsequent explantation of all VC-01 units.
Exclusion Criteria
- •There are no exclusion criteria for this trial.
Outcomes
Primary Outcomes
Incidence of adverse events reported during the study.
Time Frame: 12 months
Similar Trials
Recruiting
N/A
Bactiseal Catheter Safety Registry StudyHydrocephalusNCT06276543Integra LifeSciences Corporation200
Completed
N/A
Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopneaObstructive Sleep Apnea HypopneaObstructive Sleep ApneaOSAHNCT00849043Ventus Medical, Inc.65
Enrolling by Invitation
Phase 2
Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyNeovascular Age-related Macular DegenerationWet Macular DegenerationNCT03999801AbbVie865
Unknown
N/A
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDNeovascular Age-Related Macular Degeneration (nAMD)Gene TherapyAMDWet AMDwAMDnAMDNCT05210803AbbVie115
Enrolling by Invitation
N/A
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic RetinopathyDiabetic Retinopathy, DRNCT05296447AbbVie100